Education
About Us
Working with TipRanks
Follow Us
BioVaxys Technology (BVAXF)
OTHER OTC:BVAXF
BVAXF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.06
Previous CloseN/A
Volume36.00K
Average Volume (3M)1.14M
Market Cap
$5.82M
Enterprise Value$15.64M
Total Cash (Recent Filing)C$157.41K
Total Debt (Recent Filing)C$67.72K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Jun 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding291,525,200
10 Day Avg. Volume2,587,179
30 Day Avg. Volume1,136,290
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
BioVaxys Technology News
PremiumCompany Announcements
BioVaxys and Sona Nanotech Collaborate on Innovative Cancer Therapeutics
PremiumCompany Announcements
BioVaxys and SpayVac Expand License to Target Aquaculture Market
PremiumCompany Announcements
BioVaxys Technology Corp. Revokes Cease Trade Order and Settles Debt
PremiumCompany Announcements
BioVaxys Technology Corp. Updates on Management Cease Trade Order Status
PremiumCompany Announcements
BioVaxys Settles Debt and Closes Final Private Placement Tranche
PremiumCompany Announcements
BioVaxys Faces Potential Filing Delay Amid Recent Acquisitions---
Options Prices
Currently, No data available
---
Ownership Overview
10.02% Insiders
<0.01% Other Institutional Investors
89.98% Public Companies and
Individual Investors
BVAXF FAQ
What was BioVaxys Technology’s price range in the past 12 months?
BioVaxys Technology lowest stock price was $0.02 and its highest was $0.06 in the past 12 months.
What is BioVaxys Technology’s market cap?
BioVaxys Technology’s market cap is $5.82M.
When is BioVaxys Technology’s upcoming earnings report date?
BioVaxys Technology’s upcoming earnings report date is Jun 26, 2025 which is in 49 days.
How were BioVaxys Technology’s earnings last quarter?
BioVaxys Technology released its earnings results on Mar 31, 2025. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is BioVaxys Technology overvalued?
According to Wall Street analysts BioVaxys Technology’s price is currently Overvalued.
Does BioVaxys Technology pay dividends?
BioVaxys Technology does not currently pay dividends.
What is BioVaxys Technology’s EPS estimate?
BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVaxys Technology have?
BioVaxys Technology has 291,525,200 shares outstanding.
What happened to BioVaxys Technology’s price movement after its last earnings report?
BioVaxys Technology reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioVaxys Technology?
Currently, no hedge funds are holding shares in BVAXF
---
Company Description
BioVaxys Technology
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
---
Technical Analysis
---